Leviticus Cardio successfully completes its third chronic animal study
September 10, 2018 | Monday | News
The successful completion of this third long-term chronic trial utilizing the Jarvik 2000 LVAD pump coupled with the Leviticus wireless CET system, demonstrates the desired versatility which addresses heart failure patients.
Leviticus Cardio an Israel company, which is inventors of the versatile transcutaneous Coplanar Energy Transfer (CET) system for use with implanted left ventricular assist devices (LVADs), announces the successful completion of a 90-day preclinical chronic animal study to evaluate its CET technology in combination with a commercial heart pump.
The trial was conducted at a renowned animal facility operated by the Catholic University of Leuven, in Belgium. This study marked the third successful trial of the Leviticus CET used in conjunction with a commercial heart pump.
This important achievement paves the way for first in human (FIH), expected in a matter of months.
Latest News
Market Watch